Time | Pharma Marketer

Weekly pill dispensary: A summary of the week’s healthcare marketing news

Friday, July 30th, 2010

Bonuses For GSK Pharma Sales Reps Won’t Be Tied to Sales This story really had me scratching my head. GSK has gone from 9,000+ reps to only 2,000+ reps in three years and from what I know was really pushing reps hard to sell.

Posted in: DTC | 0 Comments »

Read the full story

The Other Side of Genzyme Takeover Speculation

Thursday, July 29th, 2010

Derek Lowe submits: In his classic Where Are the Customers’ Yachts? , Fred Schwed mentions that the option market can be a good corrective when you’re talking yourself into some investment idea

Posted in: Pharma News | 0 Comments »

Read the full story

For One Drugmaker, Outsourcing Is A Problem

Wednesday, July 28th, 2010

In this day and age where drugmakers are trying harder all the time to outsource work in hopes of cutting expenses, it is worth remembering this approach can have a downside. River’s Edge Pharmaceuticals is learning this lesson

Posted in: Regulatory | 0 Comments »

Read the full story

Sanofi Will Be Concerned About Overpaying for Genzyme

Tuesday, July 27th, 2010

EP Vantage submits: The initially hazy Sanofi-Aventis rumors are gradually turning into something more concrete.

Posted in: Pharma News | 0 Comments »

Read the full story

Safety Concerns Narrow Potential for Valuable Pfizer Pipeline Candidate

Sunday, July 25th, 2010

EP Vantage submits: As the expiry of Pfizer’s ( PFE ) precious Lipitor patent looms ever closer, the company has suffered yet another setback in its bid to cover the impending gap, with news last week of further clinical trial suspensions within its phase III programme for tanezumab (PF-4383119), this time in lower back pain and diabetic neuropathy. The FDA cited the same safety concerns that led to the previous suspension of phase III osteoarthritis (OA) trials, where some patients experienced exacerbation of the disease. Now, only cancer-associated pain remains as an active development line for what had been hailed as a potential blockbuster

Posted in: Pharma News | 0 Comments »

Read the full story

On Being Voted Off the Social Media Island

Friday, July 23rd, 2010

Here’s a bit of irony.

Posted in: Digital Marketing | 0 Comments »

Read the full story

Two BP employees named in U.S. probe, WSJ reports

Friday, July 23rd, 2010

LOS ANGELES (MarketWatch) — A U.S. probe into the explosion at BP PLC’s Deepwater Horizon oil rig has named two of the company’s managers as “parties of interest,” making them potential targets in the investigation, The Wall Street Journal reported late Thursday. The report said the two men — Robert Kaluza, who oversaw operations on the rig, and Patrick O’Bryan, BP’s vice president for oil drilling — were both aboard the rig at the time of the April 20 explosion, which sunk the structure and resulted in the worst oil spill in U.S

Posted in: headlines | 0 Comments »

Read the full story

Milestones mitigate risk in biotech deals

Wednesday, July 21st, 2010

Milestone payments are becoming an increasingly familiar aspect of many biotech deals, notes Reuters ,

Posted in: Pharma News | 0 Comments »

Read the full story

“People don’t want to interact with our site they just want the basic information”

Wednesday, July 21st, 2010

In case of some of you were living in Siberia for the past 10 years: the Web is about interactivity not stagnant content. This is especially true for drug.com websites and if you’re just going to launch a site that is pretty much stagnant than save your money and buy a pizza for the team instead because you’re not going to make a difference in patients and consumers who visit your site. Earlier this year I received a call from a client who hired an interactive agency to build a great website for over $1 million

Posted in: DTC | 0 Comments »

Read the full story

Whither Accelerated Approval? ‘We Have Teeth’

Tuesday, July 20th, 2010

Two years ago, the FDA approved Avastin to combat breast cancer, even though an advisory panel determined that risks such as high blood pressure and death outweighed the benefit of slowing the spread of tumors. The agency, however, acted under its accelerated approval program and the move pumped up sales of a Roche drug that is also used to treat brain, lung and colon tumors

Posted in: Regulatory | 0 Comments »

Read the full story